Please ensure Javascript is enabled for purposes of website accessibility

FDA accepts Viela Bio application (access required)

The Food and Drug Administration has accepted for review a biologics license application from Gaithersburg-based Viela Bio Inc. for a drug in development. The application is for inebilizumab, a drug for the treatment of patients with neuromyelitis optica spectrum disorder, a  rare disease that can lead to severe disability, including blindness and paralysis. Dr. Jorn Drappa, chief ...

To purchase a reprint of this article, contact [email protected].